New medicine for orphan and Rare diseases has the capability to undoubtedly impact the lives of patients, where historically there were few or no treatments have been provided to control the sickness. The Orphan Drug Act (ODA) established in 1983 compelled producers to expand scale to treat uncommon/orphan diseases, and the orphan drug panorama has advanced drastically. Approvals for orphan drugs has doubled in the past decade, and there are over 500 applicants in the pipeline for orphan diseases.
MarketsandMarkets Digital Event on Orphan Drugs and Rare Diseases scheduled to be held on 3rd -4th December 2020 will provide valuable and necessary platform for uplifting knowledge at the forefront of drug analysis. Over the course of the conference, internationally renowned speakers can describe how their analysis journeys have developed the response towards up to date challenges. The attending specialists and trade partners will offer an incredible networking expertise.
This conference will gather scientists, researchers, entrepreneurs, academicians, medical officers, CEO’s, CSO’s and technologists from everywhere around the globe to discuss on the newest scientific advances within the field of rare diseases & orphan drugs that facilitate to form current and future challenges in drug analysis.
Executive Member of the research and ethics committee, Hospital de Clínicas de Porto Alegre (HCPA)
Senior Advisor to the Director NCATS, , NIH
Brand Director Gene Therapy/Luxturna, Region Europe, Novartis
Region Europe Brand Director Gene Therapy – Luxturn, Novartis
Non-Executive Director, Omnispirant Therapeutics
Senior Director, Business Partnerships , Within3
Vice President and General Manager, Germany and Central / Eastern Europe , Ultragenyx Pharmaceutical Inc.
Head Iberia Rare Diseases, Chiesi
Head of Commercial & Partnerships , Mendelian
Founder & CEO, Volv Global
Chief Executive Officer, WPD Pharmaceuticals Inc
